Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes
Conditions
Type 2 Diabetes Mellitus · Type2diabetes · Diabetes Mellitus, Type 2 · Diabetes · Type 2 Diabetes
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
University of Alabama, Birmingham, Alabama, United States
Central Alabama Research, Birmingham, Alabama, United States
Velocity Clinical Research, Gardena, Gardena, California, United States
Cedars-Sinai Medical Center, Los Angeles, California, United States
UCLA, Los Angeles, California, United States
Hoag Memorial Hospital Presbyterian - Digestive Health Institute, Newport Beach, California, United States
Velocity Clinical Research, Panorama City, Panorama City, California, United States
Velocity Clinical Research, Hallandale Beach, Hallandale, Florida, United States
Mayo Clinic, Jacksonville, Florida, United States
Universal Axon Clinical Research LLC, Miami, Florida, United States
University of Miami, Miami, Florida, United States
Quantum Clinical Research, Miami Beach, Florida, United States
West Orange Endocrinology, Ocoee, Florida, United States
Advent Health, Orlando, Florida, United States
Orlando Health, Orlando, Florida, United States
Health Synergy Clinical Research, West Palm Beach, Florida, United States
NorthShore University Health System, Evanston, Illinois, United States
Heartland Medical Research, Inc., Clive, Iowa, United States
Iowa Diabetes and Endocrinology Research Center, West Des Moines, Iowa, United States
John Hopkins, Baltimore, Maryland, United States
Mayo Clinic, Rochester, Minnesota, United States
Cooper Health System, Camden, New Jersey, United States
Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
The Ohio State University- Wexner Medical Center, Columbus, Ohio, United States
Velocity Clinical Research - Austin, Austin, Texas, United States
Dell Medical School, Austin, Texas, United States
IMA Clinical Research - Austin, Austin, Texas, United States
The University of Texas Health Science Center at Houston, Bellaire, Texas, United States
Velocity Clinical Research, Dallas, Dallas, Texas, United States
Southwest Medical Center, Dallas, Texas, United States
University of Texas Southwestern Medical School - William P. Clements Jr. University Hospital, Dallas, Texas, United States
Epic Medical Research, DeSoto, Texas, United States
Houston Methodist Research Institute, Houston, Texas, United States
Juno Research, LLC, Houston, Texas, United States
Texas Diabetes & Endocrinology, P.A., Round Rock, Texas, United States
Diabetes & Glandular Disease Clinic, P.A., San Antonio, Texas, United States
IMA Clinical Research - San Antonio, San Antonio, Texas, United States
Mt. Olympus Medical Research, Sugar Land, Texas, United States
Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
The BMI Clinic, Double Bay, New South Wales, Australia
Royal North Shore Hospital, Saint Leonards, New South Wales, Australia
Eastern Health - Box Hill Hospital, Box Hill, Victoria, Australia
St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia
Austin Health, Heidelberg, Victoria, Australia
Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia
Study leads
Lian Cunningham, MD, PhD
Study Director
lcunningham@endogenex.com